Results for tag: "Muscarinic Acetylcholine Receptor"

The muscarinic acetylcholine receptor (mAChR) market focuses on the development of drugs targeted at the muscarinic receptors, which are a subgroup of acetylcholine receptors. mAChRs are G protein-coupled receptors that play a vital role in the central nervous system (CNS), mediating a variety of physiological functions including cognition, memory, and motor control. As such, they are a target for the treatment of neurological and psychiatric disorders such as Alzheimer's disease, schizophrenia, and Parkinson's disease. Agents acting on these receptors aim to correct the neurotransmitter imbalances underlying such conditions. Both agonists and antagonists of mAChRs have therapeutic potential, with efforts to improve selectivity and reduce side effects being a key research focus. The challenge in this market lies in the subtle balance between therapeutic efficacy and the avoidance of adverse events associated with targeting these receptors. Several companies operating in the mAChR market are engaged in the discovery and development of CNS drugs. These include large pharmaceutical corporations such as Merck & Co., Pfizer Inc., and Novartis AG. Smaller biotechnology firms like Karuna Therapeutics and ACADIA Pharmaceuticals are also actively researching this area. Collectively, this competitive landscape aims to advance pharmacological treatments that modulate the muscarinic system to manage and treat CNS disorders. Show Less Read more